Chapter 7 Part 3 Flashcards
What is the stepwise acquisition of mutations that lead to the development of cancer?
- Initial carcinogen induced mutation
- mutation affecting genomic integrity
- additional driver mutations, acquisition of cancer hallmarks
- Additional mutations and emergence of subclones
Eight fundamental changes in cell physiology considered hallmarks of CA
- self-sufficiency in growth signals
- Insensitivity to growth-inhibitory signals
- altered cell metabolism
- Evasion of apoptosis
- Limitless replicative potential
- sustained angiogenesis
- ability to invade and metastasize
- ability to evade host immune response
What is a proto-oncogene?
growth promoter, involved in normal cell division and growth
What is an oncogene?
cancer-causing gene, promote autonomous growth
What allelic mutations are needed to promote neoplasia?
Conversion of one of two alleles from proto-oncogene to an oncogene, or loss of both tumor suppressor alleles
What is an oncoprotein?
resembles normal product of proto-oncogenes but contains mutations that inactivate internal regulatory elements
Mode of action of growth factor oncogene
Growth factors can acquire the ability to synthesize their own growth factors and cause autocrine stimulation
Mode of action of growth factor receptor oncogene
constiutive, growth-factor independent tyrosine kinase activity
EGFR1 gene product and associated CA
epidermal growth factor receptor, lung adenocarcinoma
EGFR2 gene product and associated CA
HER2 tyrosine kinase, amplified in breast carcinoma
ALK proto-oncogene activation and associated CA
translocation or fusion with EML4, associated with lymphomas and adenocarcinomas of the lung
Function of RAS proteins
signal transduction from RTKs to MAPK/PI3K pathways
Common point mutation result of RAS proteins
decreased GTPase activity resulting in constitutive pro-growth signals
Cancers associated with RAS protein mutations
colon, lung, pancreatic, bladder, kidney, melanomas, hematologic, pituitary, etc.
Result of activating BRAF mutation
downstream kinase and transcription factor activation
Mode of activation of BRAF and associated CAs
point mutation, melanomas, leukemias, colon carcinoma
ABL tyrosine kinase mode of activation and associated CA
translocation of gene from C9 to C22 - BCR-ALK gene product, acute lymphoblastic leukemias and chronic myelogenous leukemia
Main actions of MYC
activates genes involved in cell growth – protein synthesis, cell cycle progression; upregulates telomerase, reprogram somatic cells to stem cells
MYC mechanism of activation in tumor and associated CA
translocation, Burkitt lymphoma
CA associated with constiutive Wnt signaling
colon carcinoma
CA associated with constiutive HH signaling
meduloblastoma
Mechanism of activation in tumor of cyclin and associated CA
Translocation - mantle cell lymphoma and multiple myeloma
Amplification - breast and esophageal CA
Mechanism of activation in tumor of CDKs and associated CA
amplification or pt mutation, glioblastoma, melanoma, sarcoma
Main function of RB
tumor suppressor protein that binds E2F transcription factors in hypophosphorylated state to prevent G1/S transition
Main function of p53
tumor suppressor, acts through p21 to cause cell cycle arrest, causes apoptosis
Proto-Oncogene mutations result in…
excessive increase in one or more normal functions encoded in gene
tumor-suppressor mutations result in…
lack of growth inhibition, requires both alleles to be damages
mutations in genes that regulate apoptosis result in…
less death, enhanced survival
mutations in DNA-repair genes result in…
impaired ability to recognize and repair nonlethal genetic damage, can result in genetic instability
APC function
inhibit WNT signaling
APC familial syndromes and CAs
familial colonic polyps and carcinomas, carcinomas of stomach, colon, pancreas; melanoma
NF1 function
inhibit RAS/MAPK signaling
NF2 function
cytoskeletal stability
NF1 familial syndromes and CAs
neurofibromatosis type 1; neuroblastoma, juvenile myeloid lukemia
NF2 familial syndromes and CAs
Neurofibromatosis type 2; schwannoma, meningioma
PTCH function
inhibitor of HH
PTCH familial syndromes and CAs
Gorlin syndrome; basal cell carcinoma, medulloblastoma